Видео с ютуба Tafasitamab

Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world data

Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selection

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphoma

Тафаситамаб, леналидомид и ритуксимаб при рецидивирующей или рефрактерной фолликулярной лимфоме (...

MAIC of epcoritamab with R-squared versus tafasitamab with R-squared in 2L+ follicular lymphoma

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL

The use of tafasitamab and lenalidomide in R/R DLBCL

The FDA approval of tafasitamab with R-squared for R/R follicular lymphoma

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in r/r fo...

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?

The Phase III InMIND study: tafasitamab plus lenalidomide and rituximab in R/R follicular lymphoma

The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials

inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL

Tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma

Dr. Burke on Research With Tafasitamab in Lymphoma

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL

RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCL

Smart Stop: lenalidomide, tafasitamab, rituximab, & acalabrutinib ± chemo in newly diagnosed DLBCL

The latest updates on tafasitamab in DLBCL